{"id":"intermittent-heparin-infusion","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding"},{"rate":null,"effect":"Heparin-induced thrombocytopenia (HIT)"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Thrombosis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Heparin is an anticoagulant that works by potentiating antithrombin III, which inactivates several blood coagulation factors (particularly factors IIa and Xa). Intermittent infusion involves administering heparin at intervals rather than continuous infusion, allowing for periodic anticoagulation while permitting some coagulation recovery between doses. This approach may reduce bleeding risk while maintaining therapeutic anticoagulation.","oneSentence":"Intermittent heparin infusion prevents blood clot formation by inhibiting thrombin and other coagulation factors through periodic intravenous administration.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:16:33.144Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Venous thromboembolism prevention"},{"name":"Acute coronary syndrome"},{"name":"Atrial fibrillation with thromboembolism risk"}]},"trialDetails":[{"nctId":"NCT07361081","phase":"","title":"Protocol-Driven Continuous Infusion Versus Intermittent Bolus Heparin During Atrial Fibrillation Ablation","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2022-09-01","conditions":"Atrial Fibrillation (AF), Ablation","enrollment":300},{"nctId":"NCT04048525","phase":"NA","title":"Cytokine Removal With CVVHD Compared to CVVH","status":"COMPLETED","sponsor":"Hospital Universitari de Bellvitge","startDate":"2013-03-13","conditions":"Cytokine Release Syndrome, Sepsis, AKI","enrollment":40},{"nctId":"NCT01935557","phase":"PHASE3","title":"Randomized Comparison of Continuous and Intermittent Heparin Infusion During Catheter Ablation of Atrial Fibrillation","status":"COMPLETED","sponsor":"Yong Seog Oh","startDate":"2012-12","conditions":"Coagulation; Intravascular","enrollment":296}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Intermittent heparin infusion","genericName":"Intermittent heparin infusion","companyName":"Yong Seog Oh","companyId":"yong-seog-oh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Intermittent heparin infusion prevents blood clot formation by inhibiting thrombin and other coagulation factors through periodic intravenous administration. Used for Venous thromboembolism prevention, Acute coronary syndrome, Atrial fibrillation with thromboembolism risk.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}